Atai Life Sciences N.V. (ATAI)

2,1300 +0,0800 (+3,90 %) À la clôture : 04:00PM EDT

Atai Life Sciences N.V.

Wallstrasse 16
Berlin 10179
Germany
49 89 2153 9035
https://www.atai.life

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 83

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Christian Angermayer	Founder & Chairman of the Supervisory Board	70k	S.O.	1978
Mr. Florian Brand	Co-Founder, MD & CEO	835,44k	S.O.	1987
Dr. Srinivas G. Rao M.D., Ph.D.	Co-Founder & Chief Scientific Officer	834,15k	S.O.	1969
Ms. Anne Johnson	Chief Financial Officer	S.O.	S.O.	1969
Dr. Michael Raven Ph.D.	Senior Vice President of Operations	S.O.	S.O.	S.O.
Mr. Frank Stegert	Vice President of Investment & Venture Management	S.O.	S.O.	1981
Mr. Ryan Barrett	Senior VP, General Counsel & Corporate Secretary	S.O.	S.O.	1981
Dr. Glenn Short Ph.D.	Senior Vice President of Early Development	S.O.	S.O.	S.O.
Dr. Sahil V. Kirpekar M.D.	Chief Business Officer	S.O.	S.O.	1986
Dr. Kevin Craig M.D.	Senior Vice President of Clinical Development	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Atai Life Sciences N.V. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.